文献速递肝病

接受聚乙二醇干扰素α治疗的慢性乙型肝炎患者中HBV特异性B细胞呈现多样的免疫应答

Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B.
PubMed 文献 · J Hepatol · 2024-07-09

研究纳入39例接受核苷(酸)类似物治疗的慢性乙型肝炎患者(序贯联合聚乙二醇干扰素α)及8例初治患者,用荧光标记HBsAg和HBcAg表征HBV特异性B细胞。治疗后仅达到功能性治愈的患者HBsAg特异性B细胞抗体分泌能力恢复,且与血清HBsAb水平正相关;HBcAg特异性B细胞则普遍呈现抗体分泌减弱。CD40L+滤泡辅助T细胞增多并与HBsAg特异性B细胞活化正相关。

要点

  • 治疗后仅功能性治愈者HBsAg特异性B细胞抗体分泌能力恢复,与血清HBsAb水平正相关。
  • HBcAg特异性B细胞治疗后抗体分泌减弱、IgG表达降低并出现IgM+非典型MBC,与是否功能性治愈无关。
  • CD40L+ Tfh细胞在PEG-IFNα治疗后增多,与HBsAg特异性B细胞活化正相关。

核心结论

  • PEG-IFNα治疗后HBsAg特异性与HBcAg特异性B细胞的抗体分泌呈不同变化,其功能差异反映在表型与亚型改变上。
  • CD40L+ Tfh细胞的存在与HBsAg特异性B细胞的活跃恢复相关。

研究设计与样本

  • 研究纳入39例接受核苷(酸)类似物治疗的慢性乙型肝炎患者,接受PEG-IFNα序贯联合治疗,另纳入8例初治患者。
  • 用荧光标记的乙型肝炎表面抗原和核心抗原(HBsAg、HBcAg)离体表征HBV特异性B细胞,流式细胞术检测频率、表型及亚群和滤泡辅助T细胞(Tfh细胞),ELISpot检测B细胞功能。

主要发现

  • 治疗期间HBsAg特异性B细胞中活化记忆B细胞(MBC)比例及IgG、CXCR3、CD38表达增加。
  • HBsAg特异性B细胞的抗体分泌能力仅在治疗后达到功能性治愈的患者中恢复,且与血清乙型肝炎表面抗体水平正相关。
  • 功能性治愈患者HBsAg特异性B细胞中可见IgG+经典MBC和浆母细胞,其表型和功能与未功能性治愈者不同。
  • HBcAg特异性B细胞治疗后抗体分泌减弱、IgG表达降低并出现IgM+非典型MBC,与是否功能性治愈无关。
  • PEG-IFNα治疗后CD40L+ Tfh细胞数量增加,并与HBsAg特异性B细胞活化正相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The changes in HBV-specific B cells in patients with chronic hepatitis B (CHB) undergoing pegylated interferon-α (PEG-IFNα) treatment and achieving functional cure remain unclear. We aimed to evaluate the alterations in HBV-specific B cells during treatment and therefore explored the mechanism of functional recovery of HBsAg-specific B cells. METHODS: We included 39 nucleos(t)ide analogue-treated patients with CHB who received sequential combination therapy with PEG-IFNα and eight treatment-naïve patients. HBV-specific B cells were characterized ex vivo using fluorescently labeled hepatitis B surface and core antigens (HBsAg and HBcAg). The frequency, phenotype, and subsets of HBV-specific B cells and follicular helper T cells (Tfh cells) were detected using flow cytometry. The functionality of HBV-specific B cells was quantified through ELISpot assays. RESULTS: During treatment, the fraction of activated memory B cells (MBCs) among HBsAg-specific B cells and the expression of IgG, CXCR3, and CD38 increased. The antibody-secretion capacity of HBsAg-specific B cells was only restored in patients achieving a functional cure after treatment and it positively correlated with serum hepatitis B surface antibody levels. The phenotype and function of HBsAg-specific B cells differed between patients with and without functional cure. Patients with functional cure exhibited IgG+ classical MBCs and plasmablasts among HBsAg-specific B cells. HBcAg-specific B cells displayed both attenuated antibody secretion with reduced IgG expression and an IgM+ atypical type of MBC after treatment, irrespective of functional cure. The number of CD40L+ Tfh cells increased after PEG-IFNα treatment and positively correlated with HBsAg-specific B-cell activation. CONCLUSIONS: After PEG-IFNα treatment, HBsAg- and HBcAg-specific B cells exhibit various changes in antibody secretion. Their functional differences are reflected in the alterations in phenotypes and subtypes. The presence of CD40L+ Tfh cells is associated with the active recovery of HBsAg-specific B cells. IMPACT AND IMPLICATIONS: HBV-related complications and hepatocellular carcinoma remain the leading causes of mortality from chronic liver disease worldwide, and a cure is rarely achieved with antiviral therapies. Elucidating the immunological mechanisms underlying the functional cure of patients with chronic hepatitis B offers a promising therapeutic strategy for viral clearance, e.g. via therapeutic vaccination. We analyzed the alterations in HBV-specific B cells in patients treated with pegylated interferon-α and identified novel pathways for immunotherapeutic boosting of B cell immunity.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhang JW, Lai RM, Wang LF, et al. Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B. J Hepatol. 2024. PMID: 38992769. doi:10.1016/j.jhep.2024.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。